The IL‐6R/gp130/p‐STAT3 axis has negative prognostic impact in both subtypes of DLBCL and can be targeted therapeutically to reduce the tumor burden in orthotopic models. Here, STAT3 is linked to diffuse large B-cell lymphoma.